Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.80 |
| ▸ | TP53 | P04637 | 1/20 | 0.80 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | NT5E | P21589 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29601320 | 0.89 | LMNA (1.00) | LMNATP53HPGDADORA2AADORA2B | |
| SCHEMBL638999 | 0.89 | LMNA (1.00) | LMNATP53HPGDADORA2AADORA2B | |
| SCHEMBL10607959 | 0.89 | LMNA (1.00) | LMNATP53HPGDADORA2AADORA2B | |
| SCHEMBL26030665 | 0.89 | LMNA (1.00) | LMNATP53HPGDADORA2AADORA2B | |
| SCHEMBL639000 | 0.89 | LMNA (1.00) | LMNATP53HPGDADORA2AADORA2B | |
| SCHEMBL23982228 | 0.89 | LMNA (1.00) | LMNATP53HPGDADORA2AADORA2B | |
| SCHEMBL7257342 | 0.88 | LMNA (0.80) | LMNATP53HPGDNT5EHIF1A | |
| Xanthosine SCHEMBL11523732 | 0.88 | LMNA (0.65) | LMNATP53HPGDNT5EHIF1A | |
| Xanthosine SCHEMBL8665102 | 0.88 | LMNA (0.65) | LMNATP53HPGDNT5EHIF1A | |
| Xanthosine SCHEMBL188120 | 0.88 | LMNA (0.65) | LMNATP53HPGDNT5EHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1446413-A4 | SYNTHESIS OF 2-ARALKOXY ADENOSINES AND 2-ALKOXYADENOSINES | KING PHARMACEUTICALS RES & DEV (US) | 2007-10-17 | — | — | EP | claimed |
| US-6951932-B2 | Synthesis of 2-aralkoxyadenosines and 2-alkoxyadenosines | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2005-10-04 | — | — | US | claimed |
| CN-1608076-A | Synthesis of 2-aralkyloxyadenosine and 2-alkoxyadenosine | KING PHARMACEUTICALS RES & DEV (US) | 2005-04-20 | — | — | CN | claimed |
| EP-1446413-A1 | SYNTHESIS OF 2-ARALKOXY ADENOSINES AND 2-ALKOXYADENOSINES | King Pharmaceuticals Research and Development Inc. (US) | 2004-08-18 | — | — | EP | claimed |
| US-20030199686-A1 | Synthesis of 2-aralkoxyadenosines and 2-alkoxyadenosines | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2003-10-23 | — | — | US | claimed |
| WO-2003035662-A1 | SYNTHESIS OF 2-ARALKOXY ADENOSINES AND 2-ALKOXYADENOSINES | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2003-05-01 | — | — | WO | claimed |
| EP-1446413-A4 | SYNTHESIS OF 2-ARALKOXY ADENOSINES AND 2-ALKOXYADENOSINES | KING PHARMACEUTICALS RES & DEV (US) | 2007-10-17 | — | — | EP | disclosed |
| CN-1935152-A | Synthesis of 2-aralkoxyadenosines and 2-alkoxyadenosines | KING PHARMACEUTICALS RES & DEV (US) | 2007-03-28 | — | — | CN | disclosed |
| US-6951932-B2 | Synthesis of 2-aralkoxyadenosines and 2-alkoxyadenosines | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2005-10-04 | — | — | US | disclosed |
| CN-1608076-A | Synthesis of 2-aralkyloxyadenosine and 2-alkoxyadenosine | KING PHARMACEUTICALS RES & DEV (US) | 2005-04-20 | — | — | CN | disclosed |
| EP-1446413-A1 | SYNTHESIS OF 2-ARALKOXY ADENOSINES AND 2-ALKOXYADENOSINES | King Pharmaceuticals Research and Development Inc. (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20030199686-A1 | Synthesis of 2-aralkoxyadenosines and 2-alkoxyadenosines | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2003-10-23 | — | — | US | disclosed |
| WO-2003035662-A1 | SYNTHESIS OF 2-ARALKOXY ADENOSINES AND 2-ALKOXYADENOSINES | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199686-A1 | Synthesis of 2-aralkoxyadenosines and 2-alkoxyadenosines | AMPD2, ADAR, ADA | LMNA 2588/4885TP53 2760/4885HPGD 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.